Understand the source comparison
How to Use DSIP for Pain Management Protocol: Model Comparison
Neuropathic Pain (CCI, SNI) 75–150 mcg/kg SC daily CT2 (early rest phase) 45–90 minutes Delta-opioid receptor upregulation + microglial IL-6 suppression Most robust evidence base; 40–55% reduction in mechanical allodynia in published models. Requires 7–10 days
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Neuropathic Pain (CCI, SNI)
- 75–150 mcg/kg SC daily
- CT2 (early rest phase)
- 45–90 minutes
- Delta-opioid receptor upregulation + microglial IL-6 suppression
- Most robust evidence base; 40–55% reduction in mechanical allodynia in published models. Requires 7–10 days continuous administration for peak effect.
- Inflammatory Pain (Carrageenan, CFA)
- 50–100 mcg/kg SC daily
- 30–60 minutes
- TNF-α and IL-1β downregulation in peripheral tissue + spinal cord
- Moderate efficacy; 25–35% reduction in thermal hyperalgesia. Works synergistically with low-dose NSAIDs in combination protocols.
- Visceral Pain (Acetic Acid Writhing)
- 100–150 mcg/kg SC single dose
- 30 min pre-challenge
- 20–40 minutes
- Central opioid pathway modulation (periaqueductal grey and rostral ventromedial medulla)
- Limited to acute models; effect duration ~4–6 hours. Not suitable for chronic visceral pain studies.
- Cancer Pain (Bone Metastasis Models)
- 100–200 mcg/kg SC daily
- CT1–CT3 (rest phase)
- 60–120 minutes
- Opioid receptor sensitisation + reduced inflammatory cytokine release from tumor microenvironment
- Emerging evidence; 30–40% improvement in spontaneous pain behaviours. Most effective when initiated before pain threshold changes occur.